Gelonghui, March 10, China Financial reported that compared with most of its peers, Chaoju Ophthalmology (2219.HK) needed less time to build a hospital and reached balance of payments more quickly. The bank believes that this shows the Group's advantages in a clustered, centralized and standardized operating system, and expects the company to achieve continuous growth through natural methods and mergers and acquisitions. The bank predicts that the company will earn 0.24 yuan per share last year, 0.29 yuan this year, and 0.36 yuan next year, which means that the compound annual growth rate will reach 22.8%; CICC's target price is HK$7.68, and the investment rating is “outperforming the industry.” The stock is currently reported at HK$555, with a total market value of HK$3.9 billion.
大行评级 | 中金：首予朝聚眼科“跑赢行业”评级 目标价7.68港元
Big Bank Ratings | CICC: For the first time, Chaoju Ophthalmology's target price of “outperforms the industry” rating is HK$7.68
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.